Di Filippo Kametani R, Miura T, Harada N, et al. 2006. Carvedilol inhibits mitochon- drial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J, 70:321–6. Kawai K, Qin F, Shite J, et al. 2004. Importance of antioxidant and antia- poptotic effects of β-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol, 287:H1003–12. Kay JD, Colan SD, Graham TP. 2001. Congestive heart failure in pediatric patients. Am Heart J, 142:923–8. Kaye DM, Johnston L, Vaddadi G, et al. 2001. Mechanisms of carvedilol action in human congestive heart failure. Hypertension, 37:1216–21. Krum H, Ninio D, MacDonald P. 2000. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart, 84:615–9. Läer S, Mir TS, Behn F, et al. 2002. Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and phar- macokinetic parameters. Am Heart J, 143:916–22. Lechat P, Packer M, Chalon S, et al. 1998. Clinical effects of beta-adrenergic blockade in chronic heart failure : a meta-analysis of double-blind, placebo-controlled randomized trials. Circulation, 98 :1184–91. Lowes BD, Gill EA, Abraham WT, et al. 1999. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol, 83:1201–5. Merit-HF. 1999. Effects of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet, 353:2001–7. Metra M, Torp-Pederson C, Swedberg K, et al. 2005. Inﬂuence of heart rate, blood pressure, and beta-blocker dose on outcome and the dif- ferences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J, 26:2259–68. Nagatsu M, Spinale FG, Koide M, et al. 2000. Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circula- tion, 101:653–9. Nakamura K, Kusano K, Nakamura Y, et al. 2002. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation, 105:2867–71. Nikolaidis LA, Poornima I, Parikh P, et al. 2006. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol, 47:1871–81. O’Laughlin MP. 1999. Congestive heart failure in children. Pediatr Clin North Am, 46:263–73. Packer M, Bristow MR, Cohn JN, et al. 1996. The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med, 334:1349–55. Packer M, Fowler MB, Roecker EB, et al. 2002. Effects of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPER- NICUS) study. Circulation, 106:2194–99. Packer M, Colucci WS, Sackner-Bernstein JD, et al. 1996. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation, 94:2793–9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. 2003. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial. Lancet, 362:7–13. Quaife RA, Gilbert EM, Christian PE, et al. 1997. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol, 78:779–84. Ratnapalan S, Grifﬁths K, Moldovan Costei A, et al. 2003. Digoxin- carvedilol interactions in children. J Pediatr, 142:572–4. Reiken S, Wehrens XHT, Vest JA, et al. 2003. β-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation, 107:2459–66. Ross RD. 2001. Medical management of chronic heart failure in children. Am J Cardiovasc Drugs, 1:37–44. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. 2004. Carvedilol in children with cardiomyopathy: 3-year experience at a single institu- tion. J Heart Lung Transpl, 23:832–8. Sabbah HN. 1999. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol, 22(Suppl 2):V16–20. Sackner-Bernstein JD, Mancini DM. 1995. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. J Am Med Assoc, 274:1462–7. Shaddy RE, Curtin EL, Sower B, et al. 2002. The pediatric randomized carvedilol trial in children with chronic heart failure: Rationale and design for The Pediatric Randomized Carvedilol Trial in Children with Heart Failure Study. Am Heart J, 144:383–9. Shaddy RE, Tani LY, Gidding SS, et al. 1999. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children : a multi-institutional experience. J Heart Lung Transpl, 18:269–74. Shaddy RE. 2000. Beta-adrenergic blockers in the treatment of pediatric heart failure. Progr Pediatr Cardiol, 12:113–8. Shaddy RE. 2001. Optimizing treatment for chronic congestive heart failure in children. Crit Care Med, 29(Suppl):S237–S240. Spicer RL. 2001. Carvedilol – new dimension in pediatric heart failure therapy. J Pediatr, 138:457–8. Stern H, Weil J, Genz T, Vogt W, et al. 1990. Captopril in children with dilated cardiomyopathy: acute and long-term effects in prospec- tive study of hemodynamic and hormonal effects. Pediatr Cardiol, 11:22–8. Waagstein F, Bristow MR, Swedberg K, et al. 1993. Beneﬁcial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy_MDC.Trial Study Group. Lancet, 342:1441–6. Williams RV, Tani LY, Shaddy RE. 2002. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transpl, 21:906–9. 854 Therapeutics and Clinical Risk Management 2007:3(5)